The total amount payable to entity for the achievement of regulatory and commercial milestones.

No definition available.

Name:	plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones
Namespace Prefix:	plx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The maximum amount payable to the entity to cover development costs under agreement.

+ References

No definition available.

+ Details

Name:	plx_AdditionalAmountsPayableToCoverDevelopmentCosts
Namespace Prefix:	plx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaborative arrangement profit sharing percentage.

+ References

No definition available.

+ Details

Name:	plx_CollaborativeArrangementProfitSharePercentage
Namespace Prefix:	plx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The maximum amount payable to entity to cover development costs in any year under agreement.

+ References

No definition available.

+ Details

Name:	plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear
Namespace Prefix:	plx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The cash outflow for cost incurred in the consideration for development services performed

+ References

No definition available.

+ Details

Name:	plx_PaymentInConsiderationForDevelopmentServicesPerformed
Namespace Prefix:	plx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the payment as a percentage of future net sales.

+ References

No definition available.

+ Details

Name:	plx_PaymentOnNetSalesPercentage
Namespace Prefix:	plx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash outflow for cost incurred in the connection with performance of additional studies.

+ References

No definition available.

+ Details

Name:	plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies
Namespace Prefix:	plx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of upfront,non refundable and non creditable payment receivable under the agreement for licencing rights.

+ References

No definition available.

+ Details

Name:	plx_UpfrontNonrefundableNoncreditablePaymentReceivable
Namespace Prefix:	plx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Face (par) amount of debt instrument at time of issuance.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

+ Details

Name:	us-gaap_DebtInstrumentFaceAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_TypeOfArrangementAxis=plx_PfizerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

COMMERCIALIZATION AGREEMENTS (Details) - USD ($) $ in Millions		1 Months Ended		3 Months Ended
	Dec. 31, 2019	Jul. 23, 2018	Oct. 19, 2017	Dec. 31, 2019	Oct. 31, 2015	Nov. 30, 2009
Recognized revenues related to future milestone payment				$ 4.5
Future milestone payment	$ 10.0			10.0
Pfizer [Member]
Collaborative Arrangement Profit Share Percentage						40.00%
Debt Instrument, Face Amount					$ 4.3
Chiesi US Agreement [Member]
Upfront Nonrefundable Non-Creditable Payment Receivable		$ 25.0	$ 25.0
Additional Amounts Payable To Cover Development Costs		20.0
Maximum Entitlement Of Development Costs To Cover Per Year		7.5
Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones		$ 760.0
Chiesi US Agreement [Member] \| Maximum [Member]
Payment On Net Sales Percentage		40.00%
Chiesi US Agreement [Member] \| Minimum [Member]
Payment On Net Sales Percentage		15.00%
Chiesi Ex US Agreement [Member]
Upfront Nonrefundable Non-Creditable Payment Receivable			25.0
Additional Amounts Payable To Cover Development Costs			25.0
Maximum Entitlement Of Development Costs To Cover Per Year			10.0
Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones			$ 320.0
Chiesi Ex US Agreement [Member] \| Maximum [Member]
Payment On Net Sales Percentage			35.00%
Chiesi Ex US Agreement [Member] \| Minimum [Member]
Payment On Net Sales Percentage			15.00%
Chiesi US Agreement and Chiesi Ex US Agreement [Member]
Upfront Nonrefundable Non-Creditable Payment Receivable	50.0			$ 50.0
Payments in consideration for development services performed	40.1
Payments in connection with performance of additional studies	$ 9.1